Exciting news from the biotech sector! SciRhom GmbH, a pioneering biotech company based in Germany, has successfully raised an impressive $70,000,000 in funding. Since its inception in 2016, SciRhom has been focused on developing groundbreaking antibodies targeting iRhom2, a pivotal player in inflammatory signaling pathways like TNF-alpha signaling, with the aim of revolutionizing the treatment landscape for life-threatening diseases. This generous funding injection will propel SciRhom through the crucial preclinical and early clinical stages of their monoclonal antibody development. The ultimate goal? To offer better, more effective treatments than the current options available for autoimmune diseases. With this latest funding milestone, SciRhom is on the fast track to transforming the lives of patients in need of innovative therapies.
SciRhom Secures $70 Million in Series A Funding to Revolutionize Biopharmaceuticals for Autoimmune Diseases
Recently funded · $70.0M Series aBiotechnology Research
Get the full SciRhom company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)